LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Elenco Azioni・Erasca Inc

Erasca Inc

Chiusa

10.38 2.77

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.06

Massimo

10.67

Metriche Chiave
By Trading Economics
Entrata	1.5M -29M
Dipendenti	103
EBITDA	-2M -32M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+99.6% upside

Dividendi
By Dow Jones
Utili prossimi	18 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.7B 3.2B
Apertura precedente	7.61
Chiusura precedente	10.38

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

1.39 / 1.44 Supporto e resistenza

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 mag 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mag 2026, 23:46 UTC

Discorsi di Mercato

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mag 2026, 23:33 UTC

Discorsi di Mercato

Gold Rises on Possible Position Adjustments -- Market Talk

11 mag 2026, 22:37 UTC

Discorsi di Mercato

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mag 2026, 22:32 UTC

Utili

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mag 2026, 22:02 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mag 2026, 21:49 UTC

Utili

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mag 2026, 21:42 UTC

Discorsi di Mercato

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mag 2026, 21:23 UTC

Acquisizioni, Fusioni, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mag 2026, 21:12 UTC

Utili

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mag 2026, 21:12 UTC

Utili

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

11 mag 2026, 20:44 UTC

Utili

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mag 2026, 20:43 UTC

Utili

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Rev $136.4M >CLSK

11 mag 2026, 20:30 UTC

Utili

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Cont Ops EPS $2.24 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Rev $1.6B >STE

11 mag 2026, 20:30 UTC

Utili

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Adj EPS $2.83 >STE

11 mag 2026, 20:22 UTC

Azioni calde

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mag 2026, 19:37 UTC

Utili

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mag 2026, 19:32 UTC

Discorsi di Mercato

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

99.6% in crescita

Previsioni per 12 mesi

Media 20.2 USD 99.6%

Alto 30 USD

Basso 9 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.39 / 1.44Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.